GW Pharma had a US$3 billion market cap prior to one dollar of revenue from epidiolex. I agree the value will come from the IP.
Any revenue in the next couple of years would be a small cherry on top of the value created by the clinical programs. And importantly the company now has a bullet proof balance sheet to execute, regardless of what global markets do.
- Forums
- ASX - By Stock
- General discussion
GW Pharma had a US$3 billion market cap prior to one dollar of...
-
-
- There are more pages in this discussion • 5,305 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)